alcohol use disorder

(Part three of a four-part series) As for ketamine-assisted therapy, biotech psychedelics company Awakn Life Sciences (OTC: AWAKNF) offers two distinct protocols. One is called KARE (Ketamine in the Reduction of Alcoholic Relapse) and is specific to alcohol use disorder, while the other, KAP (...

(Part one of a four-part series) The use of psychedelic-assisted psychotherapy for the treatment of mental health conditions has become a hot topic, with a growing general sense of acceptance, public discussion and reform. Each compound is proven to have specific characteristics,...

This article by Elisabetta Fato was originally published on Microdose and appears here with permission. In the last decades, there has been a growing interest in psychedelics for the treatment of mood and behavioral disorders, among which are substance use disorders. Lately, the psychedelic...

A recent clinical study led by NYU Langone found that psilocybin, the psychoactive ingredient in magic mushrooms, reduced heavy drinking by 83%, compared with a 51% reduction among those who received an antihistamine placebo. Psychedelic treatment for alcoholism became popular in the...

Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company focused on addiction treatments, has signed a licensing partnership agreement with US ketamine therapy clinics owner Revitalist Lifestyle and Wellness Ltd. (OTCQB: RVLWF), through which Revitalist will treat patients suffering from...

Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has just published its business and corporate updates. Besides researching, developing and commercializing therapeutics to treat substance and behavioral addictions, Awakn’s near-term focus is on the Alcohol Use...

The meeting, which took place on May 18 between the psychedelic pharmaceutical biotech company Clearmind Medicine Inc. (CMNDF) and the US Food and Drug Administration marks the completion the pre-IND New Drug Application stage. This will allow Clearmind to move forward in the...

This article was originally published on Psychedelic Spotlight and appears here with permission. While psychedelic studies now number in the thousands since Western research began in the 1950s, we unpack five of the most important in recent years as psychedelics are on the cusp of becoming...

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder (AUD).  The trial will determine whether OPNT002 reduces heavy drinking as measured by a change in the World Health Organization (WHO)...

Adial Pharmaceuticals Inc (NASDAQ: ADIL) has received notice from the FDA that its request for Fast Track Designation for AD04 in Alcohol Use Disorder has been denied at this time.  The FDA stated that the Company has not yet demonstrated that the product shows potential, and the...

MediciNov Inc (NASDAQ: MNOV) has announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Nature's Translational Psychiatry. The trial was funded by the Center for Study of Opioid Receptors and Drugs of Abuse. The...

Shares of nano-cap biotech Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) were volatile Thursday morning following an announcement concerning its pre-investigational new drug application meeting with the U.S Food and Drug Administration. Following the receipt of the minutes of the Type B, pre-...